Central mediation of the cannabinoid cue: Activity of a selective CB1 antagonist, SR 141716A

Behavioural Pharmacology

Volumn 7, Issue 1, 1996, Pages 65-71

  Perio A ^a   Rinaldi Carmona, M ^a   Maruani, J ^a   Barth, F ^a   Le Fur, G ^a   Soubrie P ^a  

^a SANOFI   (France)

Author keywords

Cannabinoids; CB1 receptor; Drug discrimination; Rat; SR 141716A

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID CB1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; RADIOLIGAND; RECEPTOR SUBTYPE; RIMONABANT; SR 140098; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG SELECTIVITY; HYPOTHERMIA; LIGAND BINDING; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY; STIMULUS GENERALIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; VAS DEFERENS;

EID: 0030034717     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Abood ME and Martin BR (1992) Neurobiology of marijuana abuse. Trends in Pharmacological Sciences, 13, 201-206.
2. Bramblett RD and Reggio PH (1995) An exploration of possible binding sites for cannabinoid ligands at the CB1 receptor: a hypothesized amino-alkylindole binding site. Proceedings of the 1995 Symposium on Cannabis and the Cannabinoids; June 8-10, Scottsdale, Arizone, USA, 16.
3. Colpaert FC, Niemegeers CJE and Janssen PAJ (1975) The narcotic cue: evidence for the specificity of the stimulus properties of narcotic drugs. Archives Internationales de Pharmacodynamie et de Thérapie, 218, 268-276.
4. 9-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics, 263, 1118-1126.
5. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR and Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. Journal of Pharmacology and Experimental Therapeutics, 265, 218-226.
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
7. Extance K and Goudie AJ (1981) Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacology, 73, 363-371.
8. Finney DJ (1971) Probit Analysis, 3rd edn. Cambridge University Press, Cambridge.
9. Gold LH, Balster RL, Barrett RL, Britt DT and Martin BR (1992) A comparison of the discriminative stimulus properties of delta-9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 262, 479-486.
10. Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology, 27, 429-436.
11. Howlett AC, Qualy JM and Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology, 29, 307-313.
12. Järbe TUC and Hiltunen AJ (1987) Cannabimimetic activity of cannabinol in rats and pigeons. Neuropharmacology, 26, 219-228.
13. Kallman MJ, Kaempf GL and Harris LS (1984) Discriminative stimulus properties of intraventricular delta-9-tetrahydrocannabinol. Federation Proceedings, 43, 952.
14. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
15. Mokler DJ and Rosecrans JA (1989) Discriminative stimulus properties of intracranial administration of delta-9-tetrahydrocannabinol. Drug Development Research, 16, 395-405.
16. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
17. Pacheco M, Childers SR, Arnold R, Casiano F and Ward SJ (1991) Aminoalkylindoles: actions on specific G-protein-linked receptors. Journal of Pharmacology and Experimental Therapeutics, 257, 170-183.
18. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié, Brelière J-C and Le Fur G (1994) SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters, 350 (2-3), 240-244.
19. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Brelière JC and Le Fur G (1995) Biochemical and pharmacological characterisation of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Science 56, 1941-1947.
20. Stark S and Childers SR (1994) Aminoalkylindoles bind to non-cannabinoid receptors in membranes from NG 108-15 cells. Society for Neuroscience Abstract. 228-17.
21. Vogel Z, Bayewitch M, Levy R, Matusleibovitch N, Hanus L, Benshabat S, Mechoulam R, Avidorreiss T and Barg J (1994) Binding and functional studies with the peripheral and neuronal cannabinoid receptors. Regulatory Peptides, 54, 313-314.
22. Ward SJ, Mastriani D, Casiano F and Arnold R (1990) Pravadoline: profile in isolated tissue preparations. Journal of Pharmacology and Experimental Therapeutics, 255, 1230-1239.
23. 9-tetrahydrocannabinol to cannabinoids with therapeutic potential. In: Stimulus Properties of Drugs: Ten Years of Progress (Eds FC Colpaert and JA Rosecrans), pp. 99-122. Elsevier, Amsterdam.
24. Winer BJ (1971) Statistical Principles in Experimental Design, 2nd edn. McGraw-Hill, New York.